Business Context and Reporting Period
Company: Grifols, S.A.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2010
Accounting Standards: International Financial Reporting Standards (IFRS)
Business Overview: Grifols is a global pharmaceutical company specializing in the procurement, manufacture, and sale of therapeutic products, particularly haemoderivatives (plasma-derived products), as well as diagnostic equipment and hospital supplies. The Group operates through industrial, commercial, and services segments across Spain, the United States, and international markets.
Key Financial Metrics (2010)
| Metric | 2010 (€'000) | 2009 (€'000) |
|---|---|---|
| Revenues | 990,730 | 913,186 |
| Operating Profit | 209,683 | 226,528 |
| Net Profit (Consolidated) | 115,267 | 147,570 |
| Profit Attributable to Parent | 115,513 | 147,972 |
| Net Cash from Operating Activities | 104,252 | 88,180 |
| Total Assets | 1,888,982 | 1,657,177 |
| Total Equity (Parent) | 693,040 | 566,371 |
| Total Debt (Current + Non-Current) | 875,256 | 829,407 |
| Cash and Cash Equivalents | 239,649 | 249,372 |
Note: Total Debt calculated as sum of "Loans and borrowings, bonds and other marketable securities" (Current: 191,635; Non-current: 665,385) plus "Other financial liabilities" (Current: 18,236; Non-current: 10,474).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by 8.5% (€77.5 million) compared to 2009, driven primarily by the Bioscience segment (78% of total revenue).
- Profit Decline: Despite revenue growth, Net Profit attributable to the Parent decreased by 22% (€32.5 million). This was primarily due to a significant increase in Net Finance Expenses, which rose from €22.6 million in 2009 to €51.0 million in 2010.
- Finance Costs: The surge in finance expenses was largely attributable to interest costs on corporate bonds issued in the USA in September 2009 (€31.9 million in 2010 vs. €6.8 million in 2009) and increased costs from the sale of receivables.
- Operating Cash Flow: Improved by 18% to €104.3 million, despite a €18.3 million increase in inventory levels.
- Investing Activities: Net cash used in investing activities decreased to €104.1 million (from €136.0 million in 2009), reflecting lower capital expenditures on property, plant, and equipment (€86.8 million vs. €103.4 million).
Outlook, Risks, and Unusual Items
- Talecris Acquisition: The most significant event is the agreement to acquire Talecris Biotherapeutics Holdings Corp. for approximately $3.4 billion. The transaction is subject to regulatory approval (FTC). Grifols has secured $4.5 billion in financing commitments to fund the deal. If the deal fails to receive approval, Grifols faces a potential indemnity payment of $375 million.
- Professional Services Costs: A significant portion of "Other Current Assets" (€71.2 million) and "Other Operating Expenses" (€17.0 million) relates to professional fees incurred for the Talecris acquisition. These costs are expected to be capitalized to equity or deducted from debt upon closing.
- Legal Proceedings: The Group is involved in various legal proceedings, including historical claims regarding HIV/Hepatitis C transmission and a consent decree regarding its Los Angeles plasma center. Management does not expect these to have a probable adverse financial impact, though a provision of €1.86 million was recognized for a US tax inspection.
- Financial Covenants: The Group complies with financial ratio covenants associated with its syndicated loans and corporate bonds.
- Foreign Exchange: The Group has significant exposure to the US Dollar. A 10% strengthening of the USD against the Euro would have increased equity by €35.0 million but decreased profit by €3.1 million.
Investor Verification Checklist
- Talecris Regulatory Status: Verify the current status of the US Federal Trade Commission (FTC) approval for the Talecris acquisition and the likelihood of the $375 million breakup fee.
- Debt Servicing Capacity: Assess the impact of the new $4.5 billion financing structure on future interest coverage ratios and liquidity, given the already elevated finance costs in 2010.
- Capitalization of Acquisition Costs: Confirm the accounting treatment of the €71.2 million in professional fees once the Talecris transaction closes (equity deduction vs. expense recognition).
- Inventory Levels: Review the rationale for the €43.4 million increase in inventory (Work in Progress and Finished Goods) and its impact on future working capital requirements.
- Goodwill Impairment: Monitor the €189.4 million goodwill balance, particularly related to the US Bioscience segment, for potential impairment risks if the Talecris integration faces delays or market conditions deteriorate.